而Trastuzumab Deruxtecan(T-DXd 和DS-8201)是一种新型抗体药物偶联物(antibody-drug conjugate,ADC),是HER2靶向抗体和DNA拓扑异构酶Ⅰ抑制剂德卢替康(deruxtecan,DXd)的结合物。它设计独特,药物与抗体的比例高达大约8:1,并保持稳定,从而提供了强大的细胞毒性载荷,被癌细胞中过度表达的溶酶体内化并选择性地裂——...
Trastuzumab emtansine是一种抗体偶联药物 (ADC),是HER2 靶向药物曲妥珠单抗以及微管抑制剂 DM1 的结合药物,目前是HER2阳性,先前接受过曲妥珠单抗联合紫杉醇治疗后出现疾病进展的乳腺癌患者的一线治疗手段。Trastuzumab deruxtecan(T-DXd)是一种新...
In both arms, most nausea and vomiting events were G1/2; while G≥3 events with T-DXd vs T-DM1 were 6.6% vs 0.4% for nausea and 1.6% vs 0.8% for vomiting, respectively. Rates of nausea, vomiting, and alopecia were highest in cycle 1 and lower in subsequent cycles for T-DXd. ...
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. PMID: 36495879Trastuzumab Deruxtecan: First Approval. PMID: 32144719...
(ESMO)虚拟大会上公布了头对头3期DESTINY-Breast03试验的详细阳性结果,数据显示:在先前接受过曲妥珠单抗(Trastuzumab)和紫杉烷治疗的HER2阳性不可切除性和/或转移性乳腺癌患者中,HER2靶向抗体偶联药物(ADC)Trastuzumab Deruxtecan疗效显著优于HER2靶向ADC产品Trastuzumab Emtansine(T-DM1),在多个疗效终点和关键亚组中观察...
taxane.METHODSWe conducted a phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of trastuzumab deruxtecan (a HER2 antibody–drug conjugate) with those of trastuzumab emtansine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab ...
针对T-DM1 (Emtansine)不敏感/耐受的肿瘤使用DS-8201a(DXd)可以展示良好的抗肿瘤活性,其原因可能一部分归因于能否裂解的Linker,一部分归因于Payload抑制活性的高低。 随着“万物皆可偶联”概念的兴起,与Tz偶联的Payload不再局限于细胞毒性药物开始扩展到放射性核素[13]、荧光染料[14]、Toll样受体激动剂[15]等,随之...
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. PMID: 36495879 Trastuzumab Deruxtecan: First Approval. PMID: 32144719 ...
Abstract OT-03-01: trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: a randomized, phase 3 trial (DESTINY-Breast05) Cancer Res., 81 (Supplement) (2021), 10.1158...
The researchers wanted to know whether a drug called trastuzumab deruxtecan (T-DXd) could improve participants' cancer more than the standard treatment. The standard treatment is a drug called trastuzumab emtansine (T-DM1). The researchers looked at the results of this study before it was ...